Taliya Lantsman, MD, is a hematology/oncology fellow at Beth Israel Deaconess Medical Center.

Taliya Lantsman, MD, discusses future research directions for assessing dostarlimab/chemotherapy in endometrial cancer in the real-world setting.

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

“All in all, this [retrospective analysis] demonstrates that we can use dostarlimab in addition to platinum doublets in the advanced endometrial cancer space, but we still have a lot of questions [that need to be addressed] as well.”

Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center, highlighted future research directions evaluating the treatment of dostarlimab-gxly (Jemperli) plus chemotherapy in real-world patients with advanced endometrial cancer.

In a real-world, retrospective, single-institution analysis, 27 patients with stage III/IV or recurrent endometrial cancer were included, and data showed they experienced progression-free survival (PFS) outcomes comparable to data from the phase 3 RUBY trial (NCT03981796).

These real-world data further highlight the applicability of dostarlimab plus platinum doublets in the advanced endometrial cancer space, Lantsman began. In August 2024, 

the FDA approved dostarlimab in combination with carboplatin and paclitaxel

, followed by single-agent dostarlimab, for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This expanded on 

 in July 2023, when it was indicated only for patients with mismatch repair deficient (dMMR)/microsatellite instability high disease.

However, Lantsman noted that there are remaining questions regarding the use of the combination in the real-world setting, including whether certain patients do better when dostarlimab is added to the regimen. Future research with next-generation sequencing may help parse out this question, especially as patients with mismatch repair–proficient endometrial cancer may not demonstrate greater benefits compared with those with dMMR disease, she explained.

Furthermore, patients in the real-world analysis had previously received radiation, which was not part of the RUBY trial, Lantsman said. She emphasized that this could be an opportunity for future directions. Notably, patients included in the analysis who were treated with radiation and immunotherapy simultaneously did not show an increased incidence of adverse effects (AEs), she continued. Other questions that warrant further research include the next steps of research, whether utilizing immune checkpoint inhibitors after disease progression is still feasible, and whether sequencing is important, Lantsman added.

In the analysis, those with stage IV disease with high-risk histologic subtypes were more frequently observed. Of note, the AE profile was also consistent with the safety data revealed from the RUBY trial. Nine percent of patients discontinued treatment because of AEs. Seven patients experienced disease progression, in which their post-progression treatments comprised pembrolizumab (Keytruda), antibody-drug conjugates, clinical trials, and other therapies.

Videos

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Ovarian Cancer

“At our institution, we give radiation to these patients, which differs from what we saw in RUBY, where radiation was not given. Interestingly enough, none of these patients at time of analysis had disease progression or recurrence.”

Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center, discusses the safety and efficacy of dostarlimab-gxly (Jemperli) plus chemotherapy in patients with advanced endometrial cancer according to findings from a real-world, retrospective, single-institution analysis.

The analysis enrolled 27 patients with stage III, IV, or recurrent endometrial cancer and a variety of histologies, Lantsman began. At the time of treatment initiation with dostarlimab, 56% of patients had stage IV disease, 22% had recurrent disease, and 22% had stage III disease, including stage IIIA (4%), IIIC1 (11%), and IIIC2 (7%). The cohort comprised patients with endometrioid (37%) and serous (26%) histologies, along with carcinosarcoma (11%) and other subtypes (27%).

Results from this analysis presented at the 

 showed that the combination regimen demonstrated comparable progression-free survival (PFS) outcomes to those observed in the phase 3 RUBY trial (NCT03981796), Lantsman reported. Patients with mismatch repair–deficient tumors experienced improved PFS relative to those with mismatch repair–proficient disease. Improved PFS was also noted among patients with stage III disease compared with those with stage IV or recurrent disease. Notably, all patients with stage III disease in this institutional series received radiation therapy, in contrast to the RUBY trial, where radiation was not administered, Lantsman noted. None of the patients with stage III disease who received radiation experienced immune-related adverse effects (AEs), she added.

In patients with stage IV disease, high-risk histologic subtypes were more frequently observed, Lantsman continued. The AE profile was consistent with that reported in the RUBY trial, and immune checkpoint inhibitors were generally well tolerated, with only 9% of patients discontinuing treatment due to AEs, she said. Among the 7 patients (28%) who experienced disease progression, post-progression treatments included pembrolizumab (Keytruda), antibody-drug conjugates, clinical trials, and other therapies, Lantsman stated

Of the 17 patients who remained progression-free, 71% had low-risk endometrioid histology. At the time of analysis, 2 patients had died of their disease, she noted. These findings support the feasibility of integrating dostarlimab into frontline treatment for advanced or recurrent endometrial cancer in real-world settings, Lantsman concluded.

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Taliya Lantsman, MD

Articles

Dr Lantsman on Future Directions for Evaluating Dostarlimab/Chemo in Endometrial Cancer

Dr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial Cancer